News & Events

News & Events

2-5 March

Meet the Inflamax Research team

Inflamax Research Image

Meet the Inflamax Research team at WAC 2018 AAAAI WAO Joint Congress by American Academy of Allergy, Asthma, and Immunology & World Allergy Organization in Orlando, FL from 2nd - 5th of March. Dr. Anne Marie Salapatek (Executive Vice President & CSO) & Cynthia O'Brien (Sr. Director, Business Development) will be in attendance. If you are attending and would like to meet, please contact at to coordinate a date and time for a meeting.

27 Feb

Dr. Chirag Shah at 12th Biosimilars Congregation 2018.

Dr. Chirag Shah, Director - Late Phase Trials will speak on "Regulatory considerations in Clinical Study Design of Biosimilars" at 12th Biosimilars Congregation 2018 in London, UK, on 27th & 28th February 2018. If you wish to set up a meeting with Dr. Chirag Shah, during the event contact us at

9 Jan

NJ Tobacco Research Amendment Signed into Law!

Today, after 24 months of Hill Top / Inflamax Research working with legislators and special interest groups in New Jersey, Governor Chris Christie signed Assembly Bill A3975 into law. The law, effective immediately, permits smoking in certain facilities for the purpose of medical or health-related scientific research. The bill which unanimously passed both the State Assembly in June and the Senate in December is seen as a correction to an unintentional restriction placed on research facilities in the original 2009 Clean Air Act. The legislation had strong bi-partisan support and was seen as a necessity for New Jersey to maintain the states leadership in medical research and in response to the impending FDA Deeming Regulations. The act requires proper ventilation in the facility along with physician study oversight and Investigational Review Board approval.

Read More
21 Apr

Cliantha Research acquires Inflamax Research

Cliantha Research is proud to announce the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON, Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. The patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialized pulmonary/respiratory therapeutic studies. The two New Jersey clinics were acquired by Hill Top Research (St. Petersburg, FL), a wholly owned subsidiary of Cliantha Research since 2011. With two clinical sites in the U.S., Hill Top Research can conduct HRIPT studies as per FDA guidance. Both firms are committed to a smooth, well planned integration of services in North America and India. The synergy of the combined companies expands service offerings and will drive growth.

Read More
3-7 March

The American Academy of Dermatology's Annual Meeting

Cliantha Research will be attending The American Academy of Dermatology's Annual Meeting, to be held in Orlando, Fla., March 3-7, 2017. The meeting will take place at the Orange County Convention Center, located at 9899 International Dr, Orlando, FL 32819.


Lecture & Panel Discussion at APA-India 2017

Dr. Shaifali Gupta, Laboratory Director, spoke on Biosimilars Bioanalysis: Challenges and Solutions at APA- India 2017 on 21 February’17 at Ahmedabad, India. Dr. Gupta was one of the eminent scientists in the panel discussion on 'Characterization of Large Molecules'.

2-4 Feb

Endpoint evaluation in Immunotherapy Clinical Trials

Dr. Ripal Gharia (Sr. Manager – Medical Services) and Dr. Chirag Shah (Director - Late Phase Trials) had presented a poster on Endpoint evaluation in Immunotherapy Clinical Trials: Focus on irRECIST in The Ramanbhai Foundation 8th International Symposium on Current Trends in Healthcare – “Advances in New Drug Discovery & Development” on February 2-4, 2017 at Ahmedabad, India.

20-23 March

Cliantha at DCAT 2017

Cliantha will be attending DCAT once again. Our senior leaders Naveen Sharma, John Capicchioni and Rahul Nijhawan will be in attendance. They are looking forward to meeting with you. We have number of exciting development over the past year that we'd like to share with you. The exciting developments include the addition of a new clinic in New Delhi, new ligand binding assays, new patient trials completed, updates on our Canadian capabilities, Vasoconstrictor and HRIPT studies. If you are attending and would like to meet simply respond to this email. Please provide times that you are available so we can be sure to schedule a mutually agreeable time. We look forward to seeing you in NYC. If you are not attending but a colleague is then please share this note with them.


Hill Top Research has successfully completed FDA inspection

USFDA inspection of Hill Top Research Inc. was conducted at our St. Petersburg, Florida site from Feb 22, 2017 to Mar 01, 2017 (a total of 06 working days audit for Adhesion study). The inspection concluded successfully without any 483.

20 Feb

Poster presentation at APA-India 2017

Mr. Soumen Chakraborty presented a poster on "Bioanalytical Challenges in developing and validating a biomarker assay for Tissue Factor Pathway inhibitor (TFPI) using commercial kit." at Applied Pharmaceutical Analysis (APA-India 2017) on 20 February’17 at Ahmedabad, India.

23 Oct

Biosimilars Bioanalysis; Challenges and Solutions

Dr. Shaifali Gupta, Laboratory Director, presented on ‘Biosimilars Bioanalysis; Challenges and Solutions’ - at the 49th Annual Conference of Indian Pharmacological Soceity at PGI Chandigarh on the 23rd October 2016.

19 Apr

CMIA based clinical lab instrument

Dr. Shaifali Gupta, Laboratory Director, presented the poster titled "Challenges in estimation of FSH for pharmacokinetic study by Architect i1000 (CMIA based clinical lab instrument) and commercial kits" at 10th WRIB conference in April, 2016. This was awarded the BEST poster of the conference.

19 Oct

Adis journal, Drug Safety; Volume 39, Issue 10, October 2016

Dr. Shaifali Gupta, Laboratory Director, presented at the 16th Annual Conference of International Society of Pharmacovigilance held at Agra on the 19th October 2016. Abstract (P100) – “Occurrence of Anti-erythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin” has been published in Adis journal, Drug Safety; Volume 39, Issue 10, October 2016.

Regulatory Inspections

Goverment of India Facilities inspected & approved by Drugs Controller General of India
Last inspection in Nov 2015 by
Austria (2 times)
Inspected facility in Nov 2006 by
Inspection facility in jan 2009 by
Last inspection in March 2017 by
USFDA (17 times)
Last inspection in April 2017 by
UK MHRA (2 times)
Last inspection in March 2013 by
WHO (3 times)
Inspected facility in July 2013 by
Thai MOH
Last inspected by Ministry of Health of Turkey in April 2013
Inspected facility in April 2011 by